Investor Snapshot

Sienna identifies, develops and commercialises reagents and in vitro diagnostic tests that target an unmet need. Sienna has built a strong team and a global scientific, clinical, and commercial partner network.

Sienna has a proven track record of taking products through research and development to market launch, with their first IVD test for hTERT now available for sale through a global network of distribution partners.


Current work programs are focussed on:

  • Market penetration of the telomerase technology platform in current IVD registered markets
  • Global market expansion for existing product
  • Commercialisation of new IVD tests that utilise Sienna's unique NETs technology
  • Scientific R&D both internal and through global partners to research expanded utility of telomerase product 
  • The search for additional biomarkers to feed the Sienna development and commercialisation engine    



Name Sienna Cancer Diagnostics Ltd. (ASX: SDX)
Business Description Sienna is a medical technology company that develops and commercialises in-vitro diagnostic products for the pathology market.
History Originally incorporated in Sydney, the Company is now headquartered on the outskirts of Melbourne in a business park alongside many other medical technology companies, both large and small. A public unlisted company until August 2017, Sienna started trading on the ASX as a public listed company on August 3rd, 2017.
Shares on issue 395,132,839
Company structure  Public listed company 
Location  Head office and laboratory based at the Small Technologies Cluster, 1 Dalmore Drive, Scoresby, VIC 3179, Australia 
Auditor  Walker Wayland NSW
Chartered Accountants
8th Floor, 55 Hunter St
Sydney, NSW 2000 Australia Tel: +61-2- 9951-5400
Investor Relations 

Kyahn Williamson 
+61 3 8866 1200                                

Company Secretary  Tony Di Pietro 
+61 (3) 8288 2141
Share Registry 

Link Market Services
Locked Bag A14
Sydney South, NSW 1235

Toll-free: 1300-554-474 (Australia only)
International: +61-1300-554-474

Sign up for updates